Status:
COMPLETED
Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma
Lead Sponsor:
Zhou Chengzhi
Conditions:
Lung Adenocarcinoma Stage IV
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The single arm clinical study is to evaluate the efficacy and safety of Tislelizumab combined with Bevacizumab and albumin paclitaxel in the treatment of advanced lung adenocarcinoma. All of the patie...
Detailed Description
Patients who meet the inclusion criteria will receive Tislelizumab combined with Bevacizumab and albumin paclitaxel for 4 cycles. If there is no disease progression, the patient will continue to recei...
Eligibility Criteria
Inclusion
- lung adenocarcinoma stage Ⅳ(according AJCC 8)
- received EGFR-TKI for 1 line and disease progression
- EGFR T790M negative
- ECOG PS 0-2
Exclusion
- histology of mixed NSCLC with squamous cell carcinoma, neuroendocrine carcinoma and small cell carcinoma.
- have received checkpoint inhibitor.
- uncontrolled pleural effusion, pericardial effusion, or ascites after appropriate intervention
- any unstable systemic disease
- patients who were treated with systemic glucocorticoids (\>10mg/ day prednisone therapeutic dose) or other immunosuppressive drugs within 14 days prior to the initial administration or during the study period
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2023
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04310943
Start Date
March 1 2021
End Date
December 1 2023
Last Update
March 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhou Chengzhi
Guangzhou, Guangdong, China, 510120